Merck News (NYSE:MRK)

DateTimeSource
Headline
04/25/20178:00AMPRNUSAmerica's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community
America's Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community Merck, the American Diabetes Association and Celebrity Voices Offer Tips to Help People Tackle Their Obstacles Head On PR Newswire KENILWORTH, N.J., April 25, 2017 KENILWORTH, N.J., April 25, 2017 /PRNewswire/ -- Merck (NYSE:... More...>>
04/24/20176:51PMDJNVaunted Ebola Vaccine Faces Questions
By Thomas M. Burton and Michelle Hackman The deadly Ebola outbreak in West Africa two years ago, the worst in recorded history, led to a vaccine that seemingly would stop the next Ebola epidemic in its tracks. In December, doctors from the World Health Organization, Doctors Without Borders and other groups reported in... More...>>
04/22/20177:00AMBWMerck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Findings Presented at The International Liver Congress™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic... More...>>
04/21/201710:00AMBWReal-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir & Grazopr...
Study Evaluated VA Population with High Incidence of Co-Morbidities Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered ZEPATIER® in... More...>>
04/20/20179:00AMBWMerck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa
Merck, known as MSD outside the United States and Canada, announced today a $300,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa. The donation will be offered to 10 NGOs beginning this year, and will... More...>>
04/19/20178:00AMBWMerck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company’s established and investigational infectious disease medicines at this year’s 27th European Congress of Clinical Microbiology and... More...>>
04/18/20172:07PMBWTogo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) congratulate President Faure Gnassingbé, the government and the people of Togo for becoming the first country in Africa recognized by the World Health Organization to have eliminated lymphatic filariasis (LF) as a public health problem. This... More...>>
04/18/20178:00AMBWTogo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem
GSK, Merck Sharp & Dohme (MSD), and the MECTIZAN® Donation Program (MDP) congratulate President Faure Gnassingbé, the government and the people of Togo for becoming the first country in Africa recognized by the World Health Organization to have eliminated lymphatic filariasis (LF) as a public health problem. This... More...>>
04/12/20175:29PMDJNPrescription-drug Shortages Help Push Up Prices of Similar Drugs
By Peter Loftus Prescription-drug supply shortages have hurt U.S. medical care in recent years. According to new research, they've also caused another side effect -- drug-price increases. A shortage of the bladder-cancer drug BCG in 2014 and 2015 led to sharp price increases for a less effective alternative treatment... More...>>
04/10/20174:30PMBWDr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. John H. Noseworthy, president and chief executive officer of Mayo Clinic, has been nominated to stand for election to the company’s board of directors. The annual election of Dr. Noseworthy and the other directors will take... More...>>
04/07/20177:30AMBWMerck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin... More...>>
04/06/201710:00AMBWMerck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency
Company Receives EPA Honor for 12th Consecutive Year Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2017 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of energy... More...>>
04/05/20176:50AMBWMerck to Present New Data on ZEPATIER® (elbasvir & grazoprevir) & Investigational Combination Therapy MK-3682B for the Treat...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on ZEPATIER® (elbasvir and grazoprevir) 50mg/100mg tablets will be presented at the upcoming International... More...>>
04/03/20176:45AMBWMerck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2
Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, May 2. During the call, company executives will provide an overview of Merck’s performance for the quarter and... More...>>
03/31/20177:00AMBWIncyte & Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat & KEYTRUDA® (pembr...
Clinical Program Now Includes Seven Registrational Trials Across Five Tumor Types Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational... More...>>
03/24/20178:13AMBWEuropean Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients ...
Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BV Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the... More...>>
03/22/20174:05PMBWMerck Animal Health Completes Acquisition of Vallée S.A.
Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian Market Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in... More...>>
03/14/20175:05PMBWFDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult & Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refrac...
Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab Vedotin Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA®... More...>>
03/14/20174:43PMBWMerck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treat...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for previously treated patients... More...>>
03/10/20175:32AMPRNCANew Merck Technology Aims to Further Optimize Embryo Incubation and Assessment
New Merck Technology Aims to Further Optimize Embryo Incubation and Assessment Canada NewsWire DARMSTADT, Germany, March 10, 2017 DARMSTADT, Germany, March 10, 2017 /CNW/ - Merck integrates innovative Eeva® Test with Geri™ incubation platform, bringing individualized incubation and outcome prediction together  Geri™... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170430 14:46:30